This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Stephen P. Rashleigh, MD; David I. Kusher, PhD; James N. Endicott, MD; Anne R. Rossi, MD; Julie Y. Djeu, PhD

Arch Otolaryngol Head Neck Surg. 1996;122(5):541-547.

Abstract
Objectives
To examine the capacity of interleukin-2 (IL-2) and interleukin-12 (IL-12) to modulate the cytolytic activity of peripheral blood mononuclear cells against squamous cell carcinoma, and to determine whether peripheral blood mononuclear cells from healthy donors respond differently to IL-12 than do peripheral blood mononuclear cells from patients with head and neck squamous cell carcinoma.

Design
Case-comparison study of a consecutive sample of patients with head and neck squamous cell carcinoma who were scheduled to undergo surgical excision.

Participants
The study included 10 patients with stage III or IV carcinoma matched with 10 volunteer blood donors.

Intervention
Isolated peripheral blood mononuclear cells from patients and volunteers were treated with IL-2, 10 U/mL and 100 U/mL; IL-12,1 U/mL or 10 U/mL; or a combination of IL-2 and IL-12.

Results
The combination of IL-2 and IL-12 consistently produced the greatest activation of cytolysis than either cytokine alone at all concentrations tested. This increased activity against a squamous cell carcinoma cell line was seen in lymphocytes from volunteers and patients.

Conclusion
Our findings suggest a new treatment regimen for the patient with head and neck cancer that uses immunomodulation with a combination of cytokines.

(Arch Otolaryngol Head Neck Surg. 1996;122:541-547)

Author Affiliations
From the Division of Otolaryngology—Head and Neck Surgery (Drs Rashleigh and Endicott) and the Department of Biochemistry, Immunology Program (Drs Kusher, Rossi, and Djeu), University of South Florida School of Medicine, Tampa. Dr Rashleigh is now in private practice in Savannah, Ga. Drs Kusher and Rossi are now with the Department of Pediatrics, All Children's Hospital, St Petersburg, Fla.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Combination Nonviral Murine Interleukin 2 and Interleukin 12 Gene Therapy and Radiotherapy for Head and Neck Squamous Cell Carcinoma
Xian et al.
Arch Otolaryngol Head Neck Surg 2005;131:1079-1085.
ABSTRACT | FULL TEXT  

Effects of Combined Therapy With Interleukin 2 and Interleukin 12 Gene-Transfected Tumor Vaccine for Head and Neck Carcinoma
Kimura et al.
Arch Otolaryngol Head Neck Surg 2003;129:1181-1185.
ABSTRACT | FULL TEXT  

Combination Nonviral Interleukin 2 and Interleukin 12 Gene Therapy for Head and Neck Squamous Cell Carcinoma
Li et al.
Arch Otolaryngol Head Neck Surg 2001;127:1319-1324.
ABSTRACT | FULL TEXT  

Complete Regression of Established Spontaneous Mammary Carcinoma and the Therapeutic Prevention of Genetically Programmed Neoplastic Transition by IL-12/Pulse IL-2: Induction of Local T Cell Infiltration, Fas/Fas Ligand Gene Expression, and Mammary Epithelial Apoptosis
Wigginton et al.
J. Immunol. 2001;166:1156-1168.
ABSTRACT | FULL TEXT